financetom
Business
financetom
/
Business
/
Idea, Vodafone likely to pay DoT 'under protest’, to file appeal in Supreme Court
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Idea, Vodafone likely to pay DoT 'under protest’, to file appeal in Supreme Court
Jul 18, 2018 8:08 AM

After the Department of Telecommunications (DoT) did not pay any heed to Idea Cellular and Vodafone India’s requests to re-consider the dues amount for merger approval, sources with direct knowledge suggested that the telecom companies have decided to pay up under protest.

Sources also suggested that Idea and Vodafone are likely to appeal against this move in the Supreme Court.

The number two and three telecom service providers are likely to clear dues worth Rs 7,268 crore in the next few weeks to get the final nod from the DoT to go ahead and create the largest telecom company by merging the Indian operations.

However, Idea and Vodafone decided to go ahead with the payment to avoid any more delay to the merger, which was announced in March 2017.

The DoT has asked Idea to give a bank guarantee of Rs 3,342 crore for one-time spectrum charges and Vodafone to pay Rs 3,926 crore in cash towards market price for non-auctioned airwaves held by the company.

‘Under Protest’ means payor reserves right to object to the obligation and if the telecom companies win the case, they can get a refund from the DoT.

Idea and Vodafone declined to make any comment on CNBC-TV18’s query on the subject.

Idea and Vodafone have a recent legal precedent, which may give them hope on a favourable verdict from the Supreme Court.

DoT’s claims at the time of Bharti Airtel’s acquisition of Telenor India was stayed by the Supreme Court.

Earlier, the telecom ministry on July 9 approved the merger of Vodafone and Idea that will create the country's largest mobile services operator worth over $23 billion (or over Rs 1.5 lakh crore), with a 35 per cent market share and a subscriber base of around 430 million.

First Published:Jul 18, 2018 5:08 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Altria adds $2.4 billion to share repurchase kitty, lifts earnings forecast on AB InBev stake sale
Altria adds $2.4 billion to share repurchase kitty, lifts earnings forecast on AB InBev stake sale
Mar 14, 2024
(Reuters) - Altria Group ( MO ) expanded its share buyback program by $2.4 billion and raised its annual profit forecast on Thursday, after the Marlboro maker agreed to sell about 10% of its stake in brewer Anheuser-Busch InBev. The company will also invest part of the proceeds from the sale, announced on Wednesday, to bolster its shift to alternatives...
TIMELINE-NYCB discloses loan sales, looks to integrate Signature Bank
TIMELINE-NYCB discloses loan sales, looks to integrate Signature Bank
Mar 14, 2024
(Updates with latest developments) March 7 (Reuters) - New York Community Bancorp ( NYCB ) on Thursday disclosed it had sold some loans at a gain and was working to integrate Signature Bank, the collapsed lender it had bought last year, into its overall financial reporting process. The embattled lender has been under pressure since it posted a surprise fourth-quarter...
SAIC's MG to open second Europe parts centre by the summer
SAIC's MG to open second Europe parts centre by the summer
Mar 14, 2024
PARIS (Reuters) - MG Motors, a unit of Chinese automaker SAIC, will open a second European parts centre by the summer of 2024 in France to meet the country's growing demand for its vehicles, a spokesperson told Reuters on Thursday. MG, whose electric compact car MG4 was the 23rd best-selling car in France last year after just a year on...
AstraZeneca Agrees to Buy Amolyt Pharma For Up To $1.05 Billion
AstraZeneca Agrees to Buy Amolyt Pharma For Up To $1.05 Billion
Mar 14, 2024
11:21 AM EDT, 03/14/2024 (MT Newswires) -- AstraZeneca ( AZN ) on Thursday announced a deal to buy Amolyt Pharma for up to $1.05 billion, boosting its late-stage rare disease pipeline. The UK-based biopharmaceutical company will acquire all of Amolyt's outstanding shares on a cash and debt-free basis. AstraZeneca ( AZN ) said it will pay $800 million upfront at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved